Merck wins record US$2.5b patent verdict against Gilead
New York
GILEAD Sciences Inc - the biopharmaceutical giant with a market capitalisation of US$100 billion, which Singapore's Temasek Holdings owns 1.05 per cent of, was told by a US federal jury to pay US$2.54 billion to Merck & Co for using a patented invention as the basis for its blockbuster drugs for the potentially deadly liver disease hepatitis C. This is the biggest patent-infringement verdict in US history.
The jury in Wilmington, Delaware, deliberated for less than two hours and rejected Gilead's arguments that Merck's patent is invalid. The judge in the case had already decided that Merck's patent was infringed by Gilead'…
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Google lays off employees, shifts some roles abroad amid cost cuts
Cordlife files police report against former employees for ‘potential wrongdoings’
Michelin challenges EU’s hunt for evidence of tyre cartel
First Resources denies allegations of links to firms clearing forests in Indonesia
US: Wall St opens higher on megacaps boost; earnings, Fed comments
Abbott beats quarterly profit estimates on strong medical device sales